39 related articles for article (PubMed ID: 38519799)
21. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.
Gökbuget N; Kneba M; Raff T; Trautmann H; Bartram CR; Arnold R; Fietkau R; Freund M; Ganser A; Ludwig WD; Maschmeyer G; Rieder H; Schwartz S; Serve H; Thiel E; Brüggemann M; Hoelzer D;
Blood; 2012 Aug; 120(9):1868-76. PubMed ID: 22442346
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
23. The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group.
Burmeister T; Meyer C; Schwartz S; Hofmann J; Molkentin M; Kowarz E; Schneider B; Raff T; Reinhardt R; Gökbuget N; Hoelzer D; Thiel E; Marschalek R
Blood; 2009 Apr; 113(17):4011-5. PubMed ID: 19144982
[TBL] [Abstract][Full Text] [Related]
24. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
Bassan R; Spinelli O; Oldani E; Intermesoli T; Tosi M; Peruta B; Rossi G; Borlenghi E; Pogliani EM; Terruzzi E; Fabris P; Cassibba V; Lambertenghi-Deliliers G; Cortelezzi A; Bosi A; Gianfaldoni G; Ciceri F; Bernardi M; Gallamini A; Mattei D; Di Bona E; Romani C; Scattolin AM; Barbui T; Rambaldi A
Blood; 2009 Apr; 113(18):4153-62. PubMed ID: 19141862
[TBL] [Abstract][Full Text] [Related]
25. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ;
Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850
[TBL] [Abstract][Full Text] [Related]
26. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations.
Burmeister T; Marschalek R; Schneider B; Meyer C; Gökbuget N; Schwartz S; Hoelzer D; Thiel E
Leukemia; 2006 Mar; 20(3):451-7. PubMed ID: 16424875
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.
Brüggemann M; Raff T; Flohr T; Gökbuget N; Nakao M; Droese J; Lüschen S; Pott C; Ritgen M; Scheuring U; Horst HA; Thiel E; Hoelzer D; Bartram CR; Kneba M;
Blood; 2006 Feb; 107(3):1116-23. PubMed ID: 16195338
[TBL] [Abstract][Full Text] [Related]
28. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K; Sheikh T; Aggarwal N
Semin Diagn Pathol; 2023 May; 40(3):202-215. PubMed ID: 37120350
[TBL] [Abstract][Full Text] [Related]
29. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
Burmeister T; Ströh AS; Kehden B; Trautmann H; Meyer C; Marschalek R; Larghero P; Schwartz S; Steffen B; Spriewald B; Heinicke T; Jäkel N; Westermann J; Nachtkamp K; Viardot A; Topp MS; Neumann M; Baldus CD; Gökbuget N; Brüggemann M
Leukemia; 2024 Mar; ():. PubMed ID: 38519799
[No Abstract] [Full Text] [Related]
30. Updates in
Górecki M; Kozioł I; Kopystecka A; Budzyńska J; Zawitkowska J; Lejman M
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979800
[TBL] [Abstract][Full Text] [Related]
31. Acute lymphoblastic leukemia in infants: A quarter century of nationwide efforts in Japan.
Tomizawa D; Miyamura T; Koh K; Ishii E
Pediatr Int; 2022 Jan; 64(1):e14935. PubMed ID: 34324764
[TBL] [Abstract][Full Text] [Related]
32. The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of
Esposito MT
Hemasphere; 2019 Jun; 3(3):e195. PubMed ID: 31723831
[TBL] [Abstract][Full Text] [Related]
33. Rare
Panagopoulos I; Andersen K; Eilert-Olsen M; Rognlien AG; Munthe-Kaas MC; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(2):121-131. PubMed ID: 33608309
[TBL] [Abstract][Full Text] [Related]
34. Evolution and optimization of therapies for acute lymphoblastic leukemia in infants.
Tomizawa D
Int J Hematol; 2023 Feb; 117(2):162-172. PubMed ID: 36441356
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
